Recently, testing of treatments known as cellular therapies, often called “CAR-T,” has shown promise beyond the medications ...

The team of researchers has modified the T cells so that their CAR receptors specifically recognize these RORs. As part of the joint project, the researchers are also working to make the complicated ...

This review article highlights the transformative potential of in vivo CAR T cell therapy in addressing the limitations of ...

Researchers at the University of Chicago have developed a "universal" chimeric antigen receptor (CAR) platform that offers enhanced safety, adaptability, and the potential to overcome long-standing ...

CAR-T cell therapy has demonstrated remarkable success in treating hematologic malignancies and is now expanding into solid tumors.

Chimeric antigen receptor (CAR)-T cells and T-cell therapies have been used in the treatment of various cancers for several years. In a review published in JAMA, a research team led by Christian ...

Long-term follow-up data on the use of BCMA-directed RNA chimeric antigen receptor T-cell therapy (CAR T) for refractory ...

A novel in vivo CD19 CAR-T therapy achieved complete remission in a DLBCL patient without lymphodepletion, showing sustained efficacy over three months. The therapy demonstrated safety, with no ...

Ho Chi Minh City's Blood Transfusion and Hematology Hospital is preparing to produce CAR-T cells for blood cancer treatment, ...

Southwest Research Institute (SwRI) and The University of Texas at San Antonio (UT San Antonio) are advancing a smart ...